Chinese Journal of Tissue Engineering Research ›› 2014, Vol. 18 ›› Issue (23): 3768-3772.doi: 10.3969/j.issn.2095-4344.014.23.027

Previous Articles    

Haploidentical hematopoietic stem cell transplantation in children with severe aplastic anemia

Lu Jing-yuan, Lu Quan-yi, Lin Jin-zong, Hu Jia-sheng, Hong Xiu-li, Chen Ya-mei   

  1. Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen 361004, Fujian Province, China
  • Revised:2014-03-07 Online:2014-06-04 Published:2014-06-04
  • Contact: Lu Quan-yi, M.D., Chief physician, Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen 361004, Fujian Province, China
  • About author:Lu Jing-yuan, Master, Physician, Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen 361004, Fujian Province, China
  • Supported by:

    the Major Scientific Research Project of Fujian Province, No. 2012D065

Abstract:

BACKGROUND: The main therapy of severe aplastic anemia in children is immunosuppressive therapy or stem cell transplantation, but the latter one is restricted due to few donor sources. Haploidentical hematopoietic stem cell transplantation is commonly used in leukemia, but it is still rarely reported in the treatment of aplastic anemia.

OBJECTIVE: To investigate the effect of haploidentical hematopoietic stem cell transplantation combined with placenta-derived mesenchymal stem cell transplantation for children with severe aplastic anemia.
METHODS: A 7-year-old girl who had been confirmed as having severe aplastic anemia for 1.5 years received a cotransplantation of haploidentical hematopoietic stem cells combined with placenta-derived mesenchymal stem cells on July 9th, 2012. The donor was her mother. The preconditioning regimen consisted of fludarabine, cyclophosphamide, and anti-thymocyte globulin.

RESULTS AND CONCLUSION: Time of neutrophil recovery (> 0.5×109/L) was +9 days, and hematopoietic reconstruction was complete at +12 days. The short tandem repeat analysis showed 100% donor’s genotype at +100 days. Immunosuppressive drugs were stopped at +8 months, and no acute or chronic graft-versus-host disease occurred. With a follow-up of 18 months, she was in the disease-free survival period. Our findings suggest that the cotransplantation of allogeneic haploidentical hematopoietic stem cells and placenta-derived mesenchymal stem cells is a new effective approach for children with severe aplastic anemia, which is worth exploring in the future.


中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程


全文链接:

Key words: child, anemia, aplastic, hematopoietic stem cell transplantation, immunosuppression, placenta, mesenchymal stem cell transplantation

CLC Number: